Objective: Familial combined hyperlipidemia (FCH) is characterized by elevated levels of total cholesterol (TC), triglycerides (TG) and apolipoprotein B (apo B) and is associated with premature cardiovascular disease (CVD). Other features of FCH are obesity and insulin resistance. Serum leptin levels have also been associated with obesity, insulin resistance and atherosclerosis. Leptin exerts its effect through the leptin receptor (LEPR). The aim of this study is to determine whether the Gln223Arg polymorphism in the LEPR gene contributes to FCH and its associated phenotypes. Methods: The study population consists of 37 families, comprising 644 subjects, of whom 158 subjects were diagnosed as FCH. The FCH diagnosis was based on plasma TC and TG levels, adjusted for age and gender, and absolute apo B levels, according to our recently published nomogram. The Gln223Arg polymorphism was studied by restriction fragment length polymorphism-PCR. Results: Carriers of one or two Arg alleles had an increased risk of FCH, compared to subjects homozygous for the Gln allele (OR ¼ 1.6 [95% CI 1.0-2.4]). A difference in high-density lipoprotein cholesterol (HDL-c) levels was present between carriers and non-carriers of an Arg allele, 1.21 vs 1.28 mmol/l, respectively (P ¼ 0.04), but no differences in obesity, insulin resistance and other lipid parameters were found. Conclusion: The Gln223Arg polymorphism in the LEPR gene is associated with FCH, which is supported by a significant association between HDL-c levels and the LEPR gene.
Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in humans, with a prevalence of 5.7% in the general adult population. 1 FCH is strongly associated with premature cardiovascular disease (CVD), reflected by the fact that up to 20% of the survivors of a premature myocardial infarction are affected with FCH. 2 FCH is characterized by hypercholesterolemia, hypertriglyceridemia and hyperapobetalipoproteinemia (hyperapo B).
Other phenotypes of FCH are decreased levels of highdensity lipoprotein cholesterol (HDL-c) and the presence of small dense low-density lipoprotein (sdLDL). [3] [4] [5] In addition, patients with FCH are more obese and insulin resistant. 6, 7 At present, the complex genetics of FCH, is still not fully understood. 8, 9 The fact that FCH is a genetic heterogeneous disease complicates the identification of major contributing genes. Based on the pathophysiology of FCH, several candidate genes have been evaluated, showing an association of FCH with lipoprotein lipase (LPL), 10 hepatic lipase (HL), 11 ApoAI/CIII/AIV 12 and ApoE. 13 Linkage analyses have been performed in several study populations to unravel the genetic defects causing FCH. Several regions of linkage have been identified, including a region on chromosome 1q21-23. [14] [15] [16] In this region, the upstream stimulatory factor 1 (USF1) gene has been suggested to be the gene associated with FCH. 17 Other regions of linkage identified for FCH have been reported on several other chromosomes, including 2p, 6q, 8p, 9p, 10p, 11p, 16q, 19q, 21q, 8 thereby underscoring the genetic heterogeneity of FCH. No other major gene, however, has been identified untill now. In 2002, a genome scan in 18 Dutch families provided evidence that a locus on the human chromosome 1p31, harboring the leptin receptor (LEPR) gene, contributes to apolipoprotein B (apo B) levels in patients with FCH. 18 This region segregated with plasma leptin levels, adiposity and body weight within these FCH families. 19 In the Pima Indians, markers near the LEPR gene have also been associated with obesity-related phenotypes. 20 So, the LEPR gene is a potential candidate gene of FCH. The leptin receptor is responsible for transmission of the leptin signal in the hypothalamus to several signal transducers and transcription activators and is the major leptin-binding protein in blood. 21, 22 Leptin, mainly produced by the adipose tissue, is involved in the regulation of the energy expenditure and appetite via hypothalamic receptors. 23, 24 Obese individuals have increased levels of leptin, which appear to fail to restore fat mass to normal. It is therefore believed that obesity is a state of leptin resistance. 25 The leptin receptor is a class I cytokine receptor and has several isoforms, one of which is the soluble leptin receptor present in blood. In lean subjects the largest part (60-98%) of leptin in blood is present in the bound form; however, in obese subjects the majority of leptin is unbound. 26 The leptin receptor is also present in peripheral tissues such as pancreatic beta cells, liver and skeletal muscle. 27 In these tissues, leptin is capable of stimulating lipid oxidation via the LEPR with subsequent increase in insulin sensitivity. 28, 29 The human LEPR gene is located on chromosome 1p31 23 and several single nucleotide polymorphisms (SNPs) have been described in this gene. 30 Two polymorphisms have already been described in a population of FCH patients, and were not associated with any feature of FCH. 18 A third polymorphism in the LEPR gene is Gln223Arg, located within the region encoding the extracellular domain of the leptin receptor and therefore present in all isoforms of the receptor. The amino-acid change caused by Gln223Arg is associated with a change in leptin-binding activity. 31 The
Gln223Arg polymorphism has been associated with body mass index (BMI), fat mass, leptin levels, and systolic and diastolic blood pressure in some studies; 27, 30, 32 however, other studies did not find these associations. [33] [34] [35] The aim of this study was to investigate whether there is an association between the presence of the Arg allele defined by the Gln223Arg polymorphism in the LEPR gene and FCH and its associated phenotypes.
Methods

Subjects
The study population consisted of 37 families, comprising 644 subjects, of whom 158 subjects were diagnosed as FCH patients. 36, 37 The diagnosis of FCH was based on total cholesterol (TC) and triglycerides (TG) levels adjusted for age and gender in combination with absolute apo B levels, according to our nomogram, as recently published. 37 The normolipidemic relatives (n ¼ 390) and unaffected spouses of both the FCH patients and the normolipidemic relatives (n ¼ 89), served as two independent reference groups, because of the similar genetic background of the relatives with the FCH patients. Seven subjects were not diagnosed because of missing values. Information about the presence of CVD was gathered by personal interview and physical examination performed by the clinical investigator. After withdrawal of lipid-lowering medication for 4 weeks and an overnight fast, blood was drawn by venipuncture. The ethical committee of the Radboud University Nijmegen Medical Centre approved the study protocol and the procedures followed were in accordance with institutional guidelines. All subjects gave informed consent. BMI was calculated as body weight (in kilograms) divided by the square of height (in meters). Waist circumference was obtained by using a standard cloth tape measure, measured in mm at the level of the umbilicus in the late exhalation phase while standing. Systolic and diastolic blood pressure were assessed twice with an automated blood pressure device (Dinamap; Critikon, Tampa, FL, USA) in the right arm in a sitting position after a 5-min rest period, mean blood pressures were used in our analyses.
Biochemical analyses
Plasma TC and TG were determined by enzymatic, commercially available reagents (Boehringer-Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, respectively). HDL-c was determined by the polyethylene glycol 6000 method. 38 Total plasma apo B concentrations were determined by immunonephelometry. 39 LDL subfractions were separated by single spin density gradient ultracentrifugation. A continuous variable K represents the LDL subfraction profile of each individual. A negative K-value (KoÀ0.1) reflects a more dense LDL subfraction profile, and a positive K-value (K4À0.1) reflects a more buoyant profile. [40] [41] [42] Glucose concentrations were measured in duplicate using the oxidation method (Beckman s , Glucose Analyser 2, Beckman Instruments Inc., Fullerton, CA, USA). Plasma insulin concentrations were determined using a double antibody method. 43 Insulin resistance was assessed by homeostasis model assessment (HOMA), a continuous, quantitative parameter where higher values indicate a more insulin resistant state. The HOMA-index was calculated from the fasting concentrations of insulin and glucose using the following formula: HOMA-index ¼ fasting serum insulin (mU/ml) Â fasting plasma glucose (mmol/l)/ 22.5. 44 Leptin levels were measured in duplicate in serum samples using enzyme-linked immunosorbent assay (R&D Systems, Minneapolis: Elisa Development System; Duoset s Human Leptin, Catalog no. DY398).
45
DNA extraction and genotyping DNA was isolated from peripheral blood lymphocytes by a standard method. The Gln223Arg variant was genotyped by PCR-restriction fragment length polymorphism analysis. PCR was carried out in a total volume of 50 ml containing Variables with a skewed distribution, including HOMAindex, leptin and triglyceride levels, were logarithmically transformed. The frequencies of the genotypes were tested for Hardy-Weinberg equilibrium by w 2 analysis before the analyses. Differences in anthropometric and metabolic characteristics between the genotypes were tested by means of generalized estimating equations (GEE) because of possible correlated values within families. The odds ratio as an estimate of relative risk of FCH was calculated using logistic GEE. GEE analyses were used to adjust leptin levels for BMI. Differences were considered statistically significant at P-values o0.05. All analyses described above were computed using the STATA 8.0 software (StataCorp LP, College station, TX, USA).
Results
Subject characteristics
Descriptive statistics of anthropometric and metabolic characteristics of the study population are presented in Table 1 . FCH patients are on average older than normolipidemic relatives, but younger than spouses. Evident is the higher prevalence of CVD in patients with FCH, compared to normolipidemic relatives and spouses. The mean BMI and waist circumference of patients with FCH are significantly higher, compared to normolipidemic relatives and spouses. The systolic and diastolic blood pressures are significantly higher in patients with FCH compared to the normolipidemic relatives, but not compared to the spouses. By definition, FCH patients are characterized by increased plasma TC, TG and apo B levels compared to normolipidemic relatives and spouses. Furthermore, FCH patients have decreased HDL-c levels, are more insulin resistant, as reflected by a higher HOMA-index and more sdLDL is present, as reflected by a lower K-value. Both male and female FCH patients have higher plasma leptin levels compared to normolipidemic relatives and, only within the male subjects, compared to spouses. Normolipidemic relatives are younger, have a lower BMI, waist circumference, systolic and diastolic blood pressure, TC and HDL-c levels, compared to the spouses (Table 1) .
LEPR polymorphism and FCH
The allele frequencies in the total group are 0.4 for the Arg allele and 0.6 for the Gln allele. The distribution of the alleles in the group of spouses was in Hardy-Weinberg equilibrium (P ¼ 0.75). The Arg223Arg genotype is present within 31 FCH patients (20%), 66 normolipidemic relatives (17%) and 14 spouses (16%). No differences in lipid, lipoprotein and 
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GM van der Vleuten et al insulin resistance parameters were found between subjects with the Gln223Arg or Arg223Arg genotype, therefore, pooled analyses for the carriers of the Arg allele were performed. 46 As normolipidemic relatives and spouses did not differ in frequencies of the genotypes, they were pooled into one group of controls for further analyses. In Table 2 , the genotypic distribution is presented for both the patients with FCH and the controls. In the control group, 64.2% of the subjects were carrier of one or two Arg alleles for the Gln223Arg polymorphism in the LEPR gene. In the group of FCH patients, almost 74.0% were carrier of an Arg allele. The presence of an Arg allele was associated with a 1.6 [95% CI 1.0-2.4] times increased risk for FCH ( Table 2) .
LEPR polymorphism and FCH phenotypes
As shown in Table 3 , controls carrying one or two Arg alleles had a higher BMI, waist circumference and diastolic blood pressure and decreased levels of HDL-c compared to control subjects with the Gln223Gln genotype. No differences in other lipid and lipoprotein or insulin resistance parameters were found. The mean leptin level in male and female control carriers of an Arg allele did not differ significantly from non-carriers (Table 3) . Also after adjustment of leptin levels for obesity and insulin resistance, as represented by the BMI and HOMA-index, respectively, the leptin levels did not differ between control carriers and non-carriers of an Arg allele (data not shown). Because a difference in age was observed between controls carrying an Arg allele and controls not carrying an Arg allele, analyses were adjusted for age. After adjustment for age, only the HDL-c levels were significantly different between the two genotype groups. Within the group of FCH patients, there were no significant differences in obesity, blood pressure, lipid levels and insulin resistance parameters between carriers and non-carriers of one or two Arg alleles after adjustment for age (data not shown).
Discussion
In our population of 37 well-defined FCH families, we found that carriers of one or two Arg alleles of the Gln223Arg polymorphism in the leptin receptor gene have a 1.6 times increased risk on FCH and have decreased levels of HDL-c.
There are several reasons, which suggest that the LEPR gene could be a good candidate gene for FCH. First of all, the LEPR gene is located on chromosome 1p31, within a segment to which a QTL for apo B has been mapped in another Dutch FCH population. 18 The authors also considered the LEPR gene as a candidate gene. However, genotyping two SNPs did not reveal evidence of an association between alleles of the LEPR gene and apo B levels in their study population. They did, however, not study the functional Gln223Arg polymorphism in the LEPR gene. We show that the Gln223Arg polymorphism is not associated with apo B levels. Most likely, another gene in this chromosomal region contributes to elevated apo B levels in FCH. Analyses are performed with GEE. FCH, familial combined hyperlipidemia; NL relatives, normolipidemic relatives; OR, odds ratio. a OR represents the risk associated with the presence of the Arg allele in FCH patients compared to controls, which include both the normolipidemic relatives and the spouses. Table 3 Mean values of obesity, lipid, lipoprotein and insulin resistance parameters for the carriers and non-carriers of the Arg allele in the control group
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Gln223Arg/Arg223Arg P-value P-value* FCH patients and Gln223Arg polymorphism in LEPR gene GM van der Vleuten et al Another reason, why the LEPR gene has been postulated to be a good candidate gene is the fact that the LEPR gene maps to a locus which segregates with adiposity, body weight and plasma leptin levels in pedigrees with FCH. 19 Within these pedigrees with FCH, it was found that leptin levels are associated with two polymorphic markers in the LEPR gene. 19 We now show that the Gln223Arg polymorphism is not associated with leptin levels in our population of patients with FCH. Recently, we showed that the increased leptin levels in patients with FCH are attributable to their increased adiposity and insulin resistance, suggesting that the increased leptin levels in FCH patients are not specific for FCH. 45 Reasons for the apparent discrepancy in results between the two different studies could be that van der Kallen et al. 19 did not test a functional polymorphism like we did, only polymorphic markers within the LEPR gene, and they used leptin levels as a surrogate marker of obesity; so the independent role of leptin in FCH was not investigated. The choice for the functional Gln223Arg polymorphism in the LEPR gene was based on previous studies, which suggested that the Gln223Arg polymorphism of the leptin receptor gene is associated with high blood pressure, obesity, lipids and insulin resistance, 30 we did not find an association between the Gln223Arg polymorphism in the LEPR gene and BMI and waist circumference. In the present study, we also did not find an association with blood pressure, insulin resistance, or any of the lipid and lipoprotein parameters, except for HDL-c, which was significantly lower in carriers of the Arg allele. The mechanistic implication of the association between FCH, decreased HDL-c levels and the LEPR gene, found in this study, is unclear. It is possible that the association of the Gln223Arg polymorphism in the LEPR gene with HDL-c originates from chance alone, as it is the only significant association among several tests. However, previous studies in mice and humans support the association between HDL-c and the LEPR gene. The ob/ob and db/db mice, which have specific mutations in the leptin and the leptin receptor gene, respectively, have elevated levels of HDL-c, which can be reversed by treatment with leptin. 53, 54 This suggests that leptin plays a role in the regulation of HDL-c. Also a study performed in humans by Mendez-Sanchez et al., 55 found a negative correlation between leptin levels and HDL-c. Mendez-Sanchez et al. 55 hypothesized that in obese humans, as they have high leptin levels and are leptin resistant, elevated leptin levels could have direct peripheral actions on the liver, leading to accelerated hepatic degradation of 56, 57 Leptin or the Arg allele of the LEPR gene may thus contribute to low HDL-c levels by modifying HL, PLTP, CETP or LPL levels. Recently, a genomewide linkage analysis in hypertensive sibships indicated that a locus for HDL-c levels was located on chromosome 1p, to which also the LEPR gene has been mapped. 58 So, it is conceivable that there is an association between the Gln223Arg polymorphism in the LEPR gene and HDL-c. The association of the LEPR gene with HDL-c in our study population is not supported by associations between the polymorphism in the LEPR gene and leptin levels or other serum lipid levels, while other studies, which also found an association between the Gln223Arg polymorphism and HDL-c levels, do find supportive associations with leptin or other lipid parameters. 32, 48 In conclusion, the Gln223Arg polymorphism in the leptin receptor gene is associated with an increased risk of FCH, which could be mediated by low HDL-c; however, the mechanistic implications require further study.
